Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.51 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029990 | 0.95 | TACR1 (0.52) | TACR1FKBP4PSMB9MAPTITGB1 | |
| SCHEMBL6044127 | 0.93 | TACR1 (0.49) | TACR1FKBP4PSMB9ITGB1ITGA4 | |
| SCHEMBL1078320 | 0.90 | TACR1 (0.42) | TACR1FKBP4PSMB9 | |
| SCHEMBL1882407 | 0.90 | TACR1 (0.53) | TACR1FKBP4PSMB9MAPTITGB1 | |
| SCHEMBL3513112 | 0.90 | FKBP4 (0.44) | TACR1FKBP4CMA1MAPTITGB1 | |
| SCHEMBL3314831 | 0.89 | TACR1 (0.41) | TACR1FKBP4MAPT | |
| SCHEMBL1088249 | 0.88 | TACR1 (0.41) | TACR1FKBP4MAPTITGB1ITGA4 | |
| SCHEMBL4824283 | 0.87 | PDF (0.43) | TACR1FKBP4 | |
| SCHEMBL4898024 | 0.87 | TACR1 (0.42) | TACR1FKBP4PSMB9 | |
| SCHEMBL9011368 | 0.87 | TACR1 (0.52) | TACR1FKBP4PSMB9MAPTITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7108988-B2 | Methods of identifying agents for inhibiting lentivirus replication | THE J. DAVID GLADSTONE INSTITUTES (US) | 2006-09-19 | — | — | US | claimed |
| US-20040009909-A1 | Methods for inhibiting lentivirus replication | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-15 | — | — | US | claimed |
| US-5646028-A | CLEANING | THE CLOROX COMPANY (US) | 1997-07-08 | — | — | US | claimed |
| US-5244791-A | Methods of ester hydrolysis | GENECOR INTERNATIONAL, INC. (US) | 1993-09-14 | — | — | US | claimed |
| EP-4740954-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA, INC. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3638369-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4728032-A1 | STABILIZED CLEANING COMPOSITIONS COMPRISING EDDS AND ENZYMES AND THEIR USE | BASF SE (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260098231-A1 | DETERGENT COMPOSITIONS, POLYMERS AND METHODS OF MANUFACTURING THE SAME | BASF SE (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-4722322-A1 | CLEANING COMPOSITIONS COMPRISING A PROTEASE | BASF SE (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4722324-A1 | CLEANING COMPOSITIONS COMPRISING A MANNANASE | BASF SE (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-12576140-B2 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2026-03-17 | — | — | US | disclosed |
| WO-1989009819-A1 | COMBINING MUTATIONS FOR STABILIZATION OF SUBTILISIN | GENEX CORPORATION (US) | 1989-10-19 | — | — | WO | disclosed |
| EP-0260299-A4 | MUTAGENESIS AND SCREENING METHOD AND PRODUCT. | GENEX CORP (US) | 1988-11-24 | — | — | EP | disclosed |
| US-4760025-A | Modified enzymes and methods for making same | GENENCOR, INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0260299-A1 | MUTAGENESIS AND SCREENING METHOD AND PRODUCT | Enzon Labs Inc. (US) | 1988-03-23 | — | — | EP | disclosed |
| EP-0247647-A1 | DNA mutagenesis method | GENENTECH, INC. (US) | 1987-12-02 | — | — | EP | disclosed |
| EP-0246678-A1 | Bacillus incapable of excreting subtilisin or neutral protease | GENENCOR INTERNATIONAL, INC. (US) | 1987-11-25 | — | — | EP | disclosed |
| WO-1987005050-A1 | MUTAGENESIS AND SCREENING METHOD AND PRODUCT | GENEX CORPORATION (US) | 1987-08-27 | — | — | WO | disclosed |
| EP-0130756-A1 | Procaryotic carbonyl hydrolases, methods, DNA, vectors and transformed hosts for producing them, and detergent compositions containing them | GENENCOR INTERNATIONAL, INC. (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098231-A1 | DETERGENT COMPOSITIONS, POLYMERS AND METHODS OF MANUFACTURING THE SAME | SGMS2, SGMS1, PHOSPHO1 | TACR1 4282/4885FKBP4 4683/4885PSMB9 311/4885 |
| US-12576140-B2 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | PSEN1, PSEN2, PRNP | TACR1 3837/4885FKBP4 122/4885PSMB9 3590/4885 |
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | CUTA, TMPRSS11D, KLK5 | TACR1 4542/4885FKBP4 1922/4885PSMB9 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.